---
id: 126
title: Nontuberculous Mycobacteria (NTM)
category: organisms
subcategory: mycobacteria
tags: [NTM, MAC, M-avium, M-abscessus, Lady-Windermere, clarithromycin]
difficulty: medium
---

## Question

What are the major NTM species and treatment? Use the **"MAC (Clarithro + Ethambutol + Rifamycin), Abscessus (Amikacin + Cefoxitin + Macrolide)"** framework.

## Answer

### **Major NTM Species:**

| Species | Clinical Syndromes | Risk Factors | Treatment |
|---------|-------------------|--------------|-----------|
| **MAC** (*M. avium* complex) | **Pulmonary** (nodular-bronchiectatic or fibrocavitary), **disseminated** (HIV, CD4 <50) | **Elderly women** (slender, pectus excavatum), bronchiectasis, COPD, CF | **Clarithromycin 1000mg daily** (or 500mg BID) + **ethambutol 15 mg/kg daily** + **rifampin 600mg daily** × 12 months after culture conversion |
| ***M. abscessus*** | **Pulmonary** (CF, bronchiectasis), **skin/soft tissue** (surgical sites, tattoos) | Cystic fibrosis, bronchiectasis | **IV phase:** Amikacin + cefoxitin (or imipenem) + **macrolide × 1-2 months** → **Oral phase:** Macrolide-based × 12+ months |
| ***M. kansasii*** | **Pulmonary** (mimics TB, cavitary) | HIV, COPD, smoking, mining | **Rifampin 600mg** + **ethambutol 15 mg/kg** + **isoniazid 300mg** daily × 12 months |
| ***M. marinum*** | **Skin infections** (swimming pool granuloma, fish tank granuloma) | Aquatic exposure (pools, fish tanks) | **Clarithromycin 500mg BID** OR **doxycycline 100mg BID** × 3-4 months |

### **MAC Pulmonary Disease:**

**Clinical Presentations:**

**1. Nodular-Bronchiectatic ("Lady Windermere Syndrome"):**
- **Elderly women** (typically slender, pectus excavatum, scoliosis, mitral valve prolapse)
- **Right middle lobe/lingula** involvement (bronchiectasis + nodules)
- **Chronic cough**, slowly progressive

**2. Fibrocavitary:**
- **Older men** with underlying lung disease (COPD, prior TB)
- **Upper lobe cavitary disease** (mimics TB)
- More aggressive, worse prognosis

**Diagnosis (ATS/IDSA Criteria - ALL required):**
1. **Clinical:** Pulmonary symptoms + nodular/cavitary infiltrates OR bronchiectasis + small nodules on CT
2. **Microbiologic (≥1 of):**
   - **≥2 positive sputum cultures** (different samples)
   - **≥1 positive BAL/wash culture**
   - **Transbronchial/lung biopsy** with AFB + culture-positive
3. **Exclusion:** Rule out other diagnoses

**Treatment:**
- **Clarithromycin** 1000mg daily (or 500mg BID if GI intolerance) OR **azithromycin 500-600mg daily**
- **+**
- **Ethambutol** 15 mg/kg daily
- **+**
- **Rifampin** 600mg daily (or **rifabutin** 300mg daily if drug interactions)
- **Duration:** **12 months AFTER culture conversion** (typically 18-24 months total)
- **Add amikacin or streptomycin** for severe/cavitary disease (first 2-3 months)

### **MAC Disseminated (HIV/AIDS):**

**Presentation (CD4 <50):**
- **Fever, night sweats, weight loss**
- **Diarrhea, abdominal pain**
- **Elevated alkaline phosphatase**

**Treatment:**
- **Clarithromycin 500mg BID** + **ethambutol 15 mg/kg daily** (± **rifabutin 300mg daily**)
- **Duration:** ≥12 months (lifelong if cannot achieve immune reconstitution)

**Prophylaxis:**
- **Azithromycin 1200mg weekly** OR **clarithromycin 500mg BID**
- **Start:** CD4 <50
- **Stop:** CD4 >100 × 3 months on ART

## Key Points

### ***M. abscessus* (Rapidly Growing Mycobacterium):**
- **Most difficult NTM to treat** (intrinsically resistant to many drugs)
- **Subspecies:** *M. abscessus* (resistant to macrolides via inducible erm gene), *M. massiliense* (more treatable)
- **Treatment:** **Intensive phase (IV):** Amikacin + cefoxitin (or imipenem) + macrolide × 1-2 months → **Continuation phase (oral):** Macrolide + inhaled amikacin + oral agents × 12+ months
- **ID/pulmonary consultation** essential

### **When to Treat NTM:**
- **NOT all NTM-positive cultures require treatment** (distinguish colonization from disease)
- **Treat if:** Meets ATS/IDSA diagnostic criteria + symptoms + radiographic progression
- **Consider observation** if: Minimal symptoms, stable disease, elderly/frail (treatment toxicity may outweigh benefits)

### **Macrolide Resistance:**
- **Major concern** (develops rapidly if macrolide monotherapy)
- **Screen for resistance:** Clarithromycin MIC testing
- **Mechanisms:** *erm* gene (inducible), ribosomal mutations

### **Clinical Pearls:**
- **MAC pulmonary:** Clarithromycin + ethambutol + rifampin × 12 months after culture conversion
- **"Lady Windermere":** Nodular-bronchiectatic MAC (elderly women, RML/lingula)
- ***M. abscessus*:** Most difficult to treat (ID consultation, IV amikacin + cefoxitin → prolonged oral)
- ***M. kansasii*:** Treat like TB (rifampin + ethambutol + isoniazid)
- **MAC disseminated (HIV):** Clarithromycin + ethambutol (prophylaxis if CD4 <50)
- **NOT all NTM requires treatment** (distinguish colonization from disease)

## Sources

- [ATS/IDSA: NTM Guidelines 2024]
- [CDC/NIH: MAC in HIV Guidelines 2023]

## Media

N/A
